Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome?

Angiology

Volumn 62, Issue 4, 2011, Pages 285-290

  Daskalopoulos, Georgios N ^a   Karkanaki, Artemis ^b   Karagiannis, Asterios ^b   Mikhailidis, Dimitri P ^c   Athyros, Vasilios G ^b  

^a Technical University of Larisa   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular disease risk; dyslipidemia; metabolic syndrome; obesity; phenotypes; polycystic ovary syndrome

Indexed keywords

AMINOTRANSFERASE; ANDROGEN; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

AMINOTRANSFERASE BLOOD LEVEL; ANOVULATION; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FUNCTION TEST; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PREVALENCE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 79953840968     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319711399571     Document Type: Review

References (61)

1. Knochenhauer ES, Key TJ, Kahsar- Miller M., Waggoner W., Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southern eastern United States: a prospective study. J Clin Endocrinol Metab. 1998 ; 83 (9). 3078-3082. (Pubitemid 28500937)
2. Sheehan MT Polycystic ovarian syndrome: diagnosis and management. Clin Med Res. 2004 ; 2 (1). 13-27.
3. Stein IF, Leventhal ML Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935 ; 29 (4). 181-191.
4. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic Ovary Syndrome. Boston, NY: Blackwell Scientific; 1992: 377-384.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 ; 81 (1). 19-25.
6. Azziz R., Marin C., Hoq L., Badamgarav E., Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005 ; 90 (8). 4650-4658. (Pubitemid 41159355)
7. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006 ; 91 (3). 781-785. (Pubitemid 43357736)
8. Azziz R., Carmina E., Dewailly D., et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006 ; 91 (11). 4237-4245. (Pubitemid 44833391)
9. Broekmans FJ, Knauff EA, Valkenburg O., Laven JS, Eijkemans MJ, Fauser BC PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006 ; 113 (10). 1210-1217. (Pubitemid 44401217)
10. Amato MC, Galluzzo A., Finocchiaro S., Criscimanna A., Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008 ; 69 (1). 52-60. (Pubitemid 351847260)
11. Zhang HY, Zhu FF, Xiong J., Shi XB, Fu SX Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009 ; 116 (12). 1633-1639.
12. Carmina E., Rosato F., Jannì A., Rizzo M., Longo RA Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006 ; 91 (1). 2-6. (Pubitemid 43069106)
13. Ehrmann DA Polycystic ovary syndrome. N Engl J Med. 2005 ; 352 (12). 1223-1236.
14. Carmina E., Chu MC, Longo RA, Rini GB, Lobo RA Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005 ; 90 (5). 2545-2549. (Pubitemid 40686289)
15. Rizzo M., Berneis K., Hersberger M., et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod. 2009 ; 24 (9). 2286-2292.
16. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001 ; 111 (8). 607-613. (Pubitemid 34088070)
17. Cussons AJ, Stuckey BG, Watts GF Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis. 2006 ; 185 (2). 227-239.
18. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421.
19. Castelo-Branco C., Steinvarcel F., Osorio A., Ros C., Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol Endocrinol. 2010 ; 26 (10). 736-742.
20. Carmina E., Orio F., Palomba S., et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006 ; 119 (4). 356.e1-6.
21. Fruzzetti F., Perini D., Lazzarini V., Parrini D., Genazzani AR Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril. 2009 ; 92 (2). 626-634.
22. Carmina E., Lobo RA Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest. 2007 ; 30 (2). 111-116. (Pubitemid 46614441)
23. Wijeyaratne CN, Seneviratne RD, Dahanayake S., et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod. 2011 ; 26 (1). 202-213.
24. Rizzo M., Longo RA, Guastella E., Rini GB, Carmina E. Assessing cardiovascular risk in mediterranean women with polycystic ovary syndrome. J Endocrinol Invest. 2010 Oct 15. [Epub ahead of print].
25. Karkanaki A., Piouka A., Katsikis I., Farmakiotis D., Macut D., Panidis D. Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients. Fertil Steril. 2009 ; 92 (6). 2078-2081.
26. Vryonidou A., Papatheodorou A., Tavridou A., et al. Association of hyperandrogenemic and metabolic phenotype with carotid intimamedia thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 ; 90 (5). 2740-2746. (Pubitemid 40686318)
27. Berneis K., Rizzo M., Hersberger M., et al. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract. 2009 ; 63 (1). 56-62.
28. Rizzo M., Berneis K. An update on the role of the quality of LDL in cardiovascular risk: the contribution of the universities of Palermo and Zurich. Recent Pat Cardiovasc Drug Discov. 2007 ; 2 (2). 85-88. (Pubitemid 46952440)
29. Berneis K., Rizzo M., Lazzarini V., Fruzzetti F., Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 ; 92 (1). 186-189. (Pubitemid 46067529)
30. Giallauria F., Orio F., Palomba S., Lombardi G., Colao A., Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008 ; 9 (10). 987-992.
31. Elting MW, Korsen TJ, Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2001 ; 55 (6). 767-776. (Pubitemid 34008748)
32. Chun-Sen H., Chien-Hua W., Wan-Chun C., Ching-Tzu L., Chun-Jen C., Ming-IH. Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2010 May 26. [Epub ahead of print].
33. Caballero AE Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003 ; 11 (11). 1278-1289. (Pubitemid 41127348)
34. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI Clinical and biochemical presentations of polycystic ovary syndrome among obese & nonobese women. Fertil Steril. 2009 ; 92 (6). 1960-1965.
35. Zhao X., Zhong J., Mo Y., Chen X., Chen Y., Yang D. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2010 ; 108 (2). 148-151.
36. Legro RS, Castracane VD, Kauffman RP Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004 ; 59 (2). 141-154. (Pubitemid 38140845)
37. Schröder AK, Tauchert S., Ortmann O., Diedrich K., Weiss JM Insulin resistance in patients with polycystic ovary syndrome. Ann Med. 2004 ; 36 (6). 426-439. (Pubitemid 39331414)
38. Moran L., Teed H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009 ; 15 (4). 477-488.
39. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 ; 8: 41.
40. Prapas N., Karkanaki A., Prapas I., Kalogiannidis I., Katsikis I., Panidis D. Genetics of polycystic ovary syndrome. Hippokratia. 2009 ; 13 (4). 216-223.
41. Balen AH, Conway GS, Kaltsas G., et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995 ; 10 (8). 2107-2111.
42. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990 ; 32 (2). 213-220. (Pubitemid 20039200)
43. Shaw LJ, Bairey Merz CN, Azziz R., et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008 ; 93 (3). 1276-1284. (Pubitemid 351519721)
44. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999 ; 84 (1). 165-169. (Pubitemid 29036695)
45. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 ; 22 (1). 141-146. (Pubitemid 29028311)
46. Cussons AJ, Watts GF, Burke V., Shaw JE, Zimmet PZ, Stuckey BG Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod. 2008 ; 23 (10). 2352-2358.
47. Norman RJ, Masters L., Milner CR, Wang JX, Davies MJ Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001 ; 16 (9). 1995-1998. (Pubitemid 32916235)
48. Economou F., Xyrafis X., Livadas S., et al. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones. (Athens) 2009 ; 8 (3). 199-206.
49. Tan S., Bechmann LP, Benson S., et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab. 2010 ; 95 (1). 343-348.
50. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006 ; 22 (5). 873-883. (Pubitemid 43875555)
51. Athyros VG, Tziomalos K., Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010 ; 376 (9756). 1916-1922.
52. Kauffman RP, Baker TE, Baker V., Kauffman MM, Castracane VD Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol. 2010 ; 26 (1). 39-46.
53. Vacillator E., Lafoyianni S., Vryonidou A., et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010 ; 25 (1). 212-220.
54. Hossain N., Stepanova M., Afendy A., et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol. 2010 Nov 30. [Epub ahead of print].
55. Cakal E., Ustun Y., Engin-Ustun Y., Ozkaya M., Kilinç M. Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol. 2010 Jul 13. [Epub ahead of print].
56. Athyros VG, Kakafika AI, Karagiannis A., Mikhailidis DP Do we need to consider inflammatory markers when we treat atherosclerotic disease ? Atherosclerosis. 2008 ; 200 (1). 1-12.
57. Escobar-Morreale HF, Luque-Ramírez M., González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2010 Dec 17. [Epub ahead of print].
58. Makedos A., Goulis DG, Papanikolaou A., Panidis D. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study. Angiology. 2010 ; 61 (6). 595-601.
59. Wild RA, Carmina E., Diamanti-Kandarakis E., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 ; 95 (5). 2038-2049.
60. Florakis D., Diamanti-Kandarakis E., Katsikis I., et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 2008 ; 32 (4). 692-699. (Pubitemid 351536017)
61. Shroff R., Syrop CH, Davis W., Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007 ; 88 (5). 1389-1395. (Pubitemid 350030974)